Receptor tyrosine kinase antibody arrays used in this study clearly indicated differences in receptor activation levels in two cell lines with WT EGFR, which prompted us to investigate ErbB family receptor inhibitors in NSCLC. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.